tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascelia Pharma Converts Outstanding Convertibles, Extends Cash Runway

Story Highlights
Ascelia Pharma Converts Outstanding Convertibles, Extends Cash Runway

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Ascelia Pharma AB ( (SE:ACE) ).

Ascelia Pharma announced that Fenja Capital II A/S has requested the conversion of all outstanding convertibles, resulting in the issuance of 2,218,933 new ordinary shares. This conversion increases the total number of outstanding shares and slightly dilutes the existing shares by approximately 1.88%. The company’s cash runway is now extended into the second quarter of 2026, which may impact its financial stability and operational planning.

More about Ascelia Pharma AB

Ascelia Pharma is a biotech company specializing in orphan oncology treatments, focusing on developing and commercializing novel drugs to meet unmet medical needs. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm.

Average Trading Volume: 999,504

Technical Sentiment Signal: Buy

Current Market Cap: SEK573.2M

For an in-depth examination of ACE stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1